keyword
https://read.qxmd.com/read/38535775/the-utility-of-spectroscopic-mri-in-stereotactic-biopsy-and-radiotherapy-guidance-in-newly-diagnosed-glioblastoma
#1
JOURNAL ARTICLE
Abinand C Rejimon, Karthik K Ramesh, Anuradha G Trivedi, Vicki Huang, Eduard Schreibmann, Brent D Weinberg, Lawrence R Kleinberg, Hui-Kuo G Shu, Hyunsuk Shim, Jeffrey J Olson
Current diagnostic and therapeutic approaches for gliomas have limitations hindering survival outcomes. We propose spectroscopic magnetic resonance imaging as an adjunct to standard MRI to bridge these gaps. Spectroscopic MRI is a volumetric MRI technique capable of identifying tumor infiltration based on its elevated choline (Cho) and decreased N-acetylaspartate (NAA). We present the clinical translatability of spectroscopic imaging with a Cho/NAA ≥ 5x threshold for delineating a biopsy target in a patient diagnosed with non-enhancing glioma...
March 20, 2024: Tomography: a Journal for Imaging Research
https://read.qxmd.com/read/38522697/harnessing-the-potential-of-nanoengineered-sirnas-carriers-for-target-responsive-glioma-therapy-recent-progress-and-future-opportunities
#2
REVIEW
Kailash Ahirwar, Ankit Kumar, Nidhi Srivastava, Shubhini A Saraf, Rahul Shukla
Past scientific testimonials in the field of glioma research, the deadliest tumor among all brain cancer types with the life span of 10-15 months after diagnosis is considered as glioblastoma multiforme (GBM). Even though the availability of treatment options such as chemotherapy, radiotherapy, and surgery, are unable to completely cure GBM due to tumor microenvironment complexity, intrinsic cellular signalling, and genetic mutations which are involved in chemoresistance. The blood-brain barrier is accountable for restricting drugs entry at the tumor location and related biological challenges like endocytic degradation, short systemic circulation, and insufficient cellular penetration lead to tumor aggression and progression...
March 22, 2024: International Journal of Biological Macromolecules
https://read.qxmd.com/read/38520591/predominance-of-mgmt-promoter-methylation-among-pakistani-glioblastoma-patients
#3
JOURNAL ARTICLE
Noor Muhammad, Samir Fasih, Bilal Malik, Shahid Hameed, Asif Loya, Muhammad Usman Rashid
BACKGROUND: Glioblastoma multiforme (GBM), the most prevalent subgroup of neuroepithelial tumors, is characterized by dismal overall survival (OS). Several studies have linked O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation to OS in GBM patients. However, MGMT methylation frequencies vary geographically and across ethnicities, with limited data for South Asian populations, including Pakistan. This study aimed to analyze MGMT promoter methylation in Pakistani GBM patients...
March 23, 2024: Molecular Biology Reports
https://read.qxmd.com/read/38520571/adjuvant-re-irradiation-vs-no-early-re-irradiation-of-resected-recurrent-glioblastoma-pooled-comparative-cohort-analysis-from-two-tertiary-centers
#4
JOURNAL ARTICLE
Christoph Straube, Stephanie E Combs, Denise Bernhardt, Jens Gempt, Bernhard Meyer, Claus Zimmer, Friederike Schmidt-Graf, Peter Vajkoczy, Arne Grün, Felix Ehret, Daniel Zips, David Kaul
BACKGROUND: The optimal management strategy for recurrent glioblastoma (rGBM) remains uncertain, and the impact of re-irradiation (Re-RT) on overall survival (OS) is still a matter of debate. This study included patients who achieved gross total resection (GTR) after a second surgery after recurrence, following the GlioCave criteria. METHODS: Inclusion criteria include being 18 years or older, having histologically confirmed locally recurrent IDHwt or IDH unknown GBM, achieving MRI-proven GTR after the second surgery, having a Karnofsky performance status of at least 60% after the second surgery, having a minimum interval of 6 months between the first radiotherapy and the second surgery, and a maximum of 8 weeks from second surgery to the start of Re-RT...
March 23, 2024: Journal of Neuro-oncology
https://read.qxmd.com/read/38519492/fbxo22-promotes-glioblastoma-malignant-progression-by-mediating-vhl-ubiquitination-and-degradation
#5
JOURNAL ARTICLE
Zhigang Shen, Tao Dong, Hongmei Yong, Chuyin Deng, Changxiu Chen, Xintian Chen, Miaolei Chen, Sufang Chu, Junnian Zheng, Zhongwei Li, Jin Bai
Glioblastoma (GBM) is the most common malignant primary brain tumor. Despite comprehensive treatment with traditional surgery, radiotherapy, and chemotherapy, the median survival rate is <14.6% and the 5-year survival rate is only 5%. FBXO22, a substrate receptor of the SCF ubiquitin ligases, has been reported to play a promoting role in melanoma, liver cancer, cervical cancer, and other cancers. However, the function of FBXO22 in GBM has not been reported. In the present study, we demonstrate that FBXO22 is highly expressed in glioma and is positively correlated with worse pathological features and shorter survival of GBM patients...
March 23, 2024: Cell Death Discovery
https://read.qxmd.com/read/38516683/ccna2-and-nek2-regulate-glioblastoma-progression-by-targeting-the-cell-cycle
#6
JOURNAL ARTICLE
Hao-Yu Zhou, Yi-Chang Wang, Tuo Wang, Wei Wu, Yi-Yang Cao, Bei-Chen Zhang, Mao-De Wang, Ping Mao
Glioblastoma (GBM) is characterized by significant heterogeneity, leading to poor survival outcomes for patients, despite the implementation of comprehensive treatment strategies. The roles of cyclin A2 (CCNA2) and NIMA related kinase 2 (NEK2) have been extensively studied in numerous cancers, but their specific functions in GBM remain to be elucidated. The present study aimed to investigate the potential molecular mechanisms of CCNA2 and NEK2 in GBM. CCNA2 and NEK2 expression and prognosis in glioma were evaluated by bioinformatics methods...
May 2024: Oncology Letters
https://read.qxmd.com/read/38502052/marizomib-for-patients-with-newly-diagnosed-glioblastoma-a-randomized-phase-3-trial
#7
JOURNAL ARTICLE
Patrick Roth, Thierry Gorlia, Jaap C Reijneveld, Filip de Vos, Ahmed Idbaih, Jean-Sébastien Frenel, Emilie Le Rhun, Juan Manuel Sepulveda, James Perry, G Laura Masucci, Pierre Freres, Hal Hirte, Clemens Seidel, Annemiek Walenkamp, Slavka Lukacova, Paul Meijnders, Andre Blais, Francois Ducray, Vincent Verschaeve, Garth Nicholas, Carmen Balana, Daniela A Bota, Matthias Preusser, Sarah Nuyens, Fréderic Dhermain, Martin van den Bent, Chris J O'Callaghan, Maureen Vanlancker, Warren Mason, Michael Weller
BACKGROUND: Standard treatment for patients with newly diagnosed glioblastoma includes surgery, radiotherapy (RT) and temozolomide (TMZ) chemotherapy (TMZ/RT→TMZ). The proteasome has long been considered a promising therapeutic target because of its role as a central biological hub in tumor cells. Marizomib is a novel pan-proteasome inhibitor that crosses the blood brain barrier. METHODS: EORTC 1709/CCTG CE.8 was a multicenter, randomized, controlled, open label phase 3 superiority trial...
March 19, 2024: Neuro-oncology
https://read.qxmd.com/read/38500668/management-of-glioblastoma-in-elderly-patients-a-review-of-the-literature
#8
REVIEW
Nektarios K Mazarakis, Stephen D Robinson, Priyank Sinha, Christos Koutsarnakis, Spyridon Komaitis, George Stranjalis, Susan C Short, Paul Chumas, Georgios Giamas
High grade gliomas are the most common primary aggressive brain tumours with a very poor prognosis and a median survival of less than 2 years. The standard management protocol of newly diagnosed glioblastoma patients involves surgery followed by radiotherapy, chemotherapy in the form of temozolomide and further adjuvant temozolomide. The recent advances in molecular profiling of high-grade gliomas have further enhanced our understanding of the disease. Although the management of glioblastoma is standardised in newly diagnosed adult patients there is a lot of debate regarding the best treatment approach for the newly diagnosed elderly glioblastoma patients...
May 2024: Clinical and Translational Radiation Oncology
https://read.qxmd.com/read/38498766/x-ray-activated-nanoprodrug-for-visualization-of-cortical-microvascular-alterations-and-nir-ii-image-guided-chemo-radiotherapy-of-glioblastoma
#9
JOURNAL ARTICLE
Lichao Su, Kang Zhu, Xiaoguang Ge, Ying Wu, Jieping Zhang, Guoyu Wang, Daojia Liu, Ling Chen, Qingqing Li, Junqiang Chen, Jibin Song
The permeability of the highly selective blood-brain barrier (BBB) to anticancer drugs and the difficulties in defining deep tumor boundaries often reduce the effectiveness of glioma treatment. Thus, exploring the combination of multiple treatment modalities under the guidance of second-generation near-infrared (NIR-II) window fluorescence (FL) imaging is considered a strategic approach in glioma theranostics. Herein, a hybrid X-ray-activated nanoprodrug was developed to precisely visualize the structural features of glioma microvasculature and delineate the boundary of glioma for synergistic chemo-radiotherapy...
March 18, 2024: Nano Letters
https://read.qxmd.com/read/38496908/glioblastoma-in-the-oldest-old-clinical-characteristics-therapy-and-outcome-in-patients-aged-80-years-and-older
#10
JOURNAL ARTICLE
Christina Stadler, Dorothee Gramatzki, Emilie Le Rhun, Andreas F Hottinger, Thomas Hundsberger, Ulrich Roelcke, Heinz Läubli, Silvia Hofer, Katharina Seystahl, Hans-Georg Wirsching, Michael Weller, Patrick Roth
BACKGROUND: Incidence rates of glioblastoma in very old patients are rising. The standard of care for this cohort is only partially defined and survival remains poor. The aims of this study were to reveal current practice of tumor-specific therapy and supportive care, and to identify predictors for survival in this cohort. METHODS: Patients aged 80 years or older at the time of glioblastoma diagnosis were retrospectively identified in 6 clinical centers in Switzerland and France...
April 2024: Neuro-oncology Practice
https://read.qxmd.com/read/38492275/regoma-oss-a-large-italian-multicenter-prospective-observational-study-evaluating-the-efficacy-and-safety-of-regorafenib-in-patients-with-recurrent-glioblastoma
#11
JOURNAL ARTICLE
M Caccese, I Desideri, V Villani, M Simonelli, M Buglione, S Chiesa, E Franceschi, P Gaviani, I Stasi, C Caserta, S Brugnara, I Lolli, E Bennicelli, P Bini, A S Cuccu, S Scoccianti, M Padovan, S Gori, A Bonetti, P Giordano, A Pellerino, F Gregucci, N Riva, S Cinieri, V Internò, M Santoni, G Pernice, C Dealis, L Stievano, F Paiar, G Magni, G L De Salvo, V Zagonel, G Lombardi
BACKGROUND: In the randomized phase II REGOMA trial, regorafenib showed promising activity in patients with recurrent glioblastoma. We conducted a large, multicenter, prospective, observational study to confirm the REGOMA data in a real-world setting. PATIENTS AND METHODS: The major inclusion criteria were histologically confirmed diagnosis of glioblastoma according to the World Health Organization (WHO) 2016 classification and relapse after radiotherapy with concurrent/adjuvant temozolomide treatment, good performance status [Eastern Cooperative Oncology Group performance status (ECOG PS 0-1)] and good liver function...
March 15, 2024: ESMO Open
https://read.qxmd.com/read/38489314/integrating-and-optimizing-tonabersat-in-standard-glioblastoma-therapy-a-preclinical-study
#12
JOURNAL ARTICLE
Velislava Zoteva, Valerie De Meulenaere, Christian Vanhove, Luc Leybaert, Robrecht Raedt, Leen Pieters, Anne Vral, Tom Boterberg, Karel Deblaere
Glioblastoma (GB), a highly aggressive primary brain tumor, presents a poor prognosis despite the current standard therapy, including radiotherapy and temozolomide (TMZ) chemotherapy. Tumor microtubes involving connexin 43 (Cx43) contribute to glioma progression and therapy resistance, suggesting Cx43 inhibition as a potential treatment strategy. This research aims to explore the adjuvant potential of tonabersat, a Cx43 gap junction modulator and blood-brain barrier-penetrating compound, in combination with the standard of care for GB...
2024: PloS One
https://read.qxmd.com/read/38488900/spinal-and-cervical-nodal-metastases-in-a%C3%A2-patient-with-glioblastoma
#13
JOURNAL ARTICLE
Silvio Heinig, Thomas Aigner, Heinz-Georg Bloß, Gerhard G Grabenbauer
This article presents the rare case of a 54-year-old gentleman with primary glioblastoma developing multiple extracranial metastases 7 months after diagnosis. Initially, the patient complained of progressive headaches, confusion, and weakness of the left arm. Magnetic resonance imaging of the brain showed a right temporoparietal tumor with substantial surrounding subcortical edema and midline shift to the left. Two consecutive craniotomies resulted in complete microsurgical resection of the lesion...
March 15, 2024: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://read.qxmd.com/read/38487525/peritumoral-brain-zone-in-glioblastoma-biological-clinical-and-mechanical-features
#14
REVIEW
Alberto Ballestín, Daniele Armocida, Valentino Ribecco, Giorgio Seano
Glioblastoma is a highly aggressive and invasive tumor that affects the central nervous system (CNS). With a five-year survival rate of only 6.9% and a median survival time of eight months, it has the lowest survival rate among CNS tumors. Its treatment consists of surgical resection, subsequent fractionated radiotherapy and concomitant and adjuvant chemotherapy with temozolomide. Despite the implementation of clinical interventions, recurrence is a common occurrence, with over 80% of cases arising at the edge of the resection cavity a few months after treatment...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38486856/advancements-in-chimeric-antigen-receptor-expressing-t-cell-therapy-for-glioblastoma-multiforme-literature-review-and-future-directions
#15
REVIEW
Michael Goutnik, Alexandria Iakovidis, Megan E H Still, Rachel S F Moor, Kaitlyn Melnick, Sandra Yan, Muhammad Abbas, Jianping Huang, Ashley P Ghiaseddin
Glioblastoma multiforme (GBM) is an aggressive cancer that has been difficult to treat and often requires multimodal therapy consisting of surgery, radiotherapy, and chemotherapy. Chimeric antigen receptor-expressing (CAR-T) cells have been efficacious in treating hematological malignancies, resulting in several FDA-approved therapies. CAR-T cells have been more recently studied for the treatment of GBM, with some promising preclinical and clinical results. The purpose of this literature review is to highlight the commonly targeted antigens, results of clinical trials, novel modifications, and potential solutions for challenges that exist for CAR-T cells to become more widely implemented and effective in eradicating GBM...
2024: Neuro-oncology advances
https://read.qxmd.com/read/38481068/theory-and-application-of-ttfields-in-newly-diagnosed-glioblastoma
#16
REVIEW
Ao Yu, Juan Zeng, Jinhui Yu, Shuo Cao, Ailin Li
BACKGROUND: Glioblastoma is the most common primary malignant brain tumor in adults. TTFields is a therapy that use intermediate-frequency and low-intensity alternating electric fields to treat tumors. For patients with ndGBM, the addition of TTFields after the concurrent chemoradiotherapy phase of the Stupp regimen can improve prognosis. However, TTFields still has the potential to further prolong the survival of ndGBM patients. AIM: By summarizing the mechanism and application status of TTFields in the treatment of ndGBM, the application prospect of TTFields in ndbm treatment is prospected...
March 2024: CNS Neuroscience & Therapeutics
https://read.qxmd.com/read/38458809/brain-re-irradiation-or-chemotherapy-a-phase-ii-randomised-trial-of-re-irradiation-and-chemotherapy-in-patients-with-recurrent-glioblastoma-brioche-protocol-for-a-multi-centre-open-label-randomised-trial
#17
JOURNAL ARTICLE
Eleanor M Hudson, Samantha Noutch, Joanne Webster, Sarah R Brown, Florien W Boele, Omar Al-Salihi, Helen Baines, Helen Bulbeck, Stuart Currie, Sharon Fernandez, Jane Hughes, John Lilley, Alexandra Smith, Catherine Parbutt, Finbar Slevin, Susan Short, David Sebag-Montefiore, Louise Murray
INTRODUCTION: Glioblastoma (GBM) is the most common adult primary malignant brain tumour. The condition is incurable and, despite aggressive treatment at first presentation, almost all tumours recur after a median of 7 months. The aim of treatment at recurrence is to prolong survival and maintain health-related quality of life (HRQoL). Chemotherapy is typically employed for recurrent GBM, often using nitrosourea-based regimens. However, efficacy is limited, with reported median survivals between 5 and 9 months from recurrence...
March 8, 2024: BMJ Open
https://read.qxmd.com/read/38457839/equivalent-uniform-aerobic-dose-in-radiotherapy-for-hypoxic-tumors
#18
JOURNAL ARTICLE
Alexei V Chvetsov, Mark Muzi
Equivalent uniform aerobic dose (EUAD) is proposed for comparison of integrated cell survival in tumors with different distributions of hypoxia and radiation dose. The EUAD assumes that for any non-uniform distributions of radiation dose and oxygen enhancement ratio (OER) within a tumor, there is a uniform distribution of radiation dose under hypothetical aerobic conditions with OER=1 that produces equal integrated survival of clonogenic cells. This definition of EUAD has several advantages. First, the EUAD allows one to compare survival of clonogenic cells in tumors with intra-tumor and inter-tumor variation of radio sensitivity due to hypoxia because the cell survival is recomputed under the same benchmark oxygen level (OER=1)...
March 8, 2024: Physics in Medicine and Biology
https://read.qxmd.com/read/38456152/optimizing-adjuvant-treatment-options-for-patients-with-glioblastoma
#19
JOURNAL ARTICLE
Enzhao Zhu, Jiayi Wang, Weizhong Shi, Qi Jing, Pu Ai, Dan Shan, Zisheng Ai
BACKGROUND: This study focused on minimizing the costs and toxic effects associated with unnecessary chemotherapy. We sought to optimize the adjuvant therapy strategy, choosing between radiotherapy (RT) and chemoradiotherapy (CRT), for patients based on their specific characteristics. This selection process utilized an innovative deep learning method. METHODS: We trained six machine learning (ML) models to advise on the most suitable treatment for glioblastoma (GBM) patients...
2024: Frontiers in Neurology
https://read.qxmd.com/read/38455242/impact-of-remoteness-and-rurality-on-the-treatment-and-survival-of-patients-with-glioblastoma-in-the-north-of-scotland
#20
JOURNAL ARTICLE
Damjan Veljanoski, Raphae Barlas, Aimun A B Jamjoom, James Walkden, Graham Horgan, Rafael Moleron, Phyo Kyaw Myint, Anastasios Giamouriadis
BACKGROUND: The geographical catchment area served by the Neurosurgical Unit in Aberdeen, Scotland is the largest in the United Kingdom. We examined whether a distance-decay effect on survival exists for patients diagnosed with glioblastoma, who have to travel substantial distances for neurosurgical and oncological treatment in the north of Scotland. METHODS: Electronic medical records of adult patients with glioblastoma, referred for treatment between 2007 and 2018, who underwent surgical resection were reviewed...
April 2024: World neurosurgery: X
keyword
keyword
75725
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.